No Survival Benefit in CRPC With New Anti-Androgen

SAN FRANCISCO (MedPage Today) -- An investigational anti-androgen failed to improve overall survival in a randomized trial of men with docetaxel-treated metastatic castration-resistant prostate cancer (CRPC). via MedPageToday.com - medical news plus CME for physicians Read More Here..

For a Free Step By Step Guide for Dating Dos and Don'ts check http://end2endwebs.com

Lake forest health and fitness http://ift.tt/1kzigtx